contraindications of glp 1 agonist What are the for Glucagon-like peptide-1 (GLP-1) receptor agonists? Safety and Tolerability of Glucagon-Like

NEW YORK Food and beverage companies will have quite a lot to swallow in digesting the effects of GLP-1 weight-loss drugs on their industry, according to global business consultancy PwC

Obesity is associated with worsened outcomes in patients with ulcerative colitis on advanced therapies: A propensity matched cohort study from the U.S

Studies have found that GLP-1R is widely distributed on pancreatic and other tissues and has multiple biological effects, such as reducing neuroinflammation, promoting nerve growth, improving heart function, suppressing appetite, delaying gastric emptying, regulating blood lipid metabolism and reducing fat deposition

Why are investors betting on combination therapies like CagriSema over single-drug approaches

Despite promising findings, the lack of standardized experimental models and inconsistent GLP-1-RA dosing regimens across studies limits direct comparison and reproducibility

However, if the A1c is 60 mg/mmol, or progressive increase in UACR despite appropriate therapy, eGFR 30% increase in serum creatinine within 3 months of starting SGLT2i, ACEi, or ARB, inability to achieve target BP, or signs/symptoms of another underlying kidney disease, such as glomerulonephritis